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Abstract
Background: Anti-viral prophylaxis is used to prevent the transmission of influenza. We studied serological 
confirmation of 2009 Influenza A (H1N1) infections during oseltamivir prophylaxis and after cessation of prophylaxis.
Methods: Between 22 Jun and 16 Jul 09, we performed a cohort study in 3 outbreaks in the Singapore military where 
post-exposure oseltamivir ring chemoprophylaxis (75 mg daily for 10 days) was administered. The entire cohort was 
screened by RT-PCR (with HA gene primers) using nasopharyngeal swabs three times a week. Three blood samples 
were taken for haemagglutination inhibition testing - at the start of outbreak, 2 weeks after completion of 10 day 
oseltamivir prophylaxis, and 3 weeks after the pandemic's peak in Singapore. Questionnaires were also administered to 
collect clinical symptoms.
Results: 237 personnel were included for analysis. The overall infection rate of 2009 Influenza A (H1N1) during the 
three outbreaks was 11.4% (27/237). This included 11 index cases and 16 personnel (7.1%) who developed four-fold or 
higher rise in antibody titres during oseltamivir prophylaxis. Of these 16 personnel, 8 (3.5%) were symptomatic while 
the remaining 8 personnel (3.5%) were asymptomatic and tested negative on PCR. Post-cessation of prophylaxis, an 
additional 23 (12.1%) seroconverted. There was no significant difference in mean fold-rise in GMT between those who 
seroconverted during and post-prophylaxis (11.3 vs 11.7, p = 0.888). No allergic, neuropsychiatric or other severe side-
effects were noted.
Conclusions: Post-exposure oseltamivir prophylaxis reduced the rate of infection during outbreaks, and did not 
substantially increase subsequent infection rates upon cessation. Asymptomatic infections occur during prophylaxis, 
which may confer protection against future infection. Post-exposure prophylaxis is effective as a measure in mitigating 
pandemic influenza outbreaks.
Background
Anti-viral prophylaxis has been used as a strategy to pre-
vent the transmission and spread of influenza. Post-expo-
sure prophylaxis with oseltamivir, a commonly used
neuraminidase-inhibitor, has been shown to be effective
in preventing the development of clinical disease against
seasonal influenza when used against household contacts
[1,2]. Pre-exposure prophylaxis has also been successfully
used in the community [3], and in households [4] to pre-
vent transmission of influenza. For the 2009 pandemic,
post-exposure prophylaxis has been used in household
and community contacts of pandemic influenza cases [5],
as well as in pandemic influenza outbreaks in closed envi-
ronments [6].
One of the uncertainties with prophylaxis is the risk of
maintaining an immunologically naïve population which
may increase the possibility of outbreaks after the cessa-
tion of prophylaxis. One mathematical model showed
that premature cessation of prophylaxis before the pan-
demic's peak resulted in higher peak infection rates com-
pared to no prophylaxis use [7]. However, prophylaxis
may delay the spread of the virus such that the overall
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infection rate in the affected group is reduced, and may
spread out the burden of disease, thus reducing the strain
on resources and disruption of services. Currently, there
is little evidence on the actual outcome of prophylaxis in
such situations.
Chemoprophylaxis failures have been previously docu-
mented but mostly by the development of clinical influ-
enza illness among individuals receiving prophylaxis
[1,4]. However, influenza may also result in asymptomatic
infections [8], and one previous study showed that
asymptomatic infections while receiving oseltamivir pro-
phylaxis do occur [3]. Asymptomatic sero-conversion
may confer protection and increase the overall effective-
ness of antiviral prophylaxis in protecting individuals and
cohorts even after cessation by increasing herd immunity.
We performed a study in the tropical city-state of Sin-
gapore to determine symptomatic and asymptomatic
serological confirmation of 2009 Influenza A (H1N1)
infections during oseltamivir prophylaxis and after cessa-
tion of prophylaxis, in 3 separate outbreaks. The findings
will be important in the application of future chemopro-
phylaxis strategies.
Methods
We performed an observational cohort study in the Sin-
gapore military from 22 Jun 09 to 16 Jul 09. The Singa-
pore military has a mix of regular employees and
conscript personnel where all males are required to serve
after high school. These personnel live in camps during
the week and return home on weekends, resulting in a
semi-closed community with exposures to the national
community. The Singapore military identified its first
imported case of 2009 Influenza A (H1N1) on 15 Jun
2009, and on 22 Jun 2009 identified its first outbreak clus-
ter with local transmission.
In line with national protocols, cases of 2009 Influenza
A (H1N1) were determined via laboratory confirmed
infection by real-time reverse transcription polymerase
chain reaction (RT-PCR) or viral culture [9]. In addition
to the national protocol of hospital or home isolation of
cases during the early containment phase of the local epi-
demic [10], the Singapore military used the strategy of
geographical oseltamivir ring chemoprophylaxis of
affected military units with 10 days of oseltamivir 75 mg
once a day, and cohorting of the entire units (as a form of
social distancing) to prevent spread.
Epidemiological Investigations
The study was performed among 252 personnel involved
in 3 separate 2009 Influenza A (H1N1) outbreaks,
whereby post-exposure oseltamivir ring chemoprophy-
laxis was administered. At the onset of each outbreak, a
10 day course of post-exposure oseltamivir chemopro-
phylaxis was given to each cohort and they continued to
function in their normal capacity. The entire cohort was
screened by RT-PCR using nasopharyngeal swabs three
times a week, until no further positive cases were discov-
ered for three days. All confirmed cases were given a
minimum of 7 days home medical leave. The rest of the
cohort continued their regular schedule, including stay-
ing in camp during weekdays and returning home during
weekends.
In addition, three samples of 5 to 10 ml of venous blood
were taken from each participant in for serological test-
ing. The first baseline sample was taken at the start of
outbreak. The second sample was taken between 2 to 3
weeks after the completion of oseltamivir prophylaxis.
This timeframe allowed sufficient time for seroconver-
sion from infections during prophylaxis, while reducing
the likelihood of seroconversion from infections after
prophylaxis [11]. The third sample was taken 3 weeks
after the peak of the pandemic in Singapore [12], between
4 to 6 weeks after the completion of prophylaxis, to assess
for any additional seroconversion after prophyalxis.
Questionnaires were administered to collect data on
demographics, medical history, and clinical symptoms.
Written informed consent was obtained from partici-
pants, and the study was approved by the Singapore mili-
tary's Joint Medical Committee (Research) and the
Australian National University's ethics review board.
Laboratory Analysis
The nasopharyngeal swabs collected were resuspended in
3.0 ml of universal transport medium (Copan Diagnostics
Inc., USA) and sent for laboratory testing. Total nucleic
acid material was extracted using the DNA minikit (Qia-
gen, Inc, Valencia, CA, USA) according to manufacturer's
instructions and subjected to real-time PCR testing for
the presence of H1N1-2009 [13]. Briefly, 5ul of nucleic
extract was PCR-amplified with 0.8 uM of each of the for-
ward (5'-GAC AAA ATA ACA AAC GAA GCA ACT GG
- 3') and reverse primers (5'-GGG AGG CTG TTT ATA
GCA CC-3') in the presence of 0.2 uM probe (5'-6-car-
boxyfluorescein-GCA TTC GCA AT(BHQ)G GAA AGA
AAT GCT GG -3') using the Superscript III RT/Platinum
Taq mix (Invitrogen Corporation, CA, USA) according to
manufacturer's instructions. The reverse transcription
(RT) was carried out at 50°C for 30 mins, the reaction
denatured at 95°C for 2 mins, and PCR-amplified with 50
cycles consisting of 95°C for 15 sec and 55°C for 30 sec.
The RT-PCR testing was carried out on a real-time PCR
system (Applied Biosystems 7500, USA), A positive result
is defined by a fluorescence growth curve that crosses the
threshold line within 40 cycles. Sensitivity of this assay is
about 100 copies of RNA genome equivalents per reac-
tion (95% confidence level) [14].
For the blood samples, serum was extracted and tested
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dard protocols (WHO CC, 1982) at the WHO Collabo-
rating Center for Reference and Research for Influenza in
Melbourne, Australia. The serum was pretreated with
receptor destroying enzyme (RDE) (Deka Seiken Co. Ltd.,
Tokyo, Japan) at 1:4 (volume/volume), and the enzyme
inactivated by addition of an equal volume of 1.6% tri-
sodium citrate (Ajax Chemicals, Australia). Egg-grown
A/California/7/2009 A(H1N1-2009) virus was purified by
sucrose gradient, concentrated and inactivated with β-
propiolactone, to create an influenza zonal pool prepara-
tion (a gift from CSL, Australia). 25 μL of Influenza Zonal
Pool-A/California/7/2009 virus was incubated with an
equal volume of RDE-treated serum, titrated in two-fold
dilutions in phosphate buffer solution from 1:10 to
1:1280, and incubated for 1 hour. 25 μl 1% (v/v) turkey red
blood cells was added to each well and read after 30 min-
utes. Controls for the HI assay were performed with posi-
tive ferret sera (sera collected from naive ferrets infected
with A/California/7/2009 H1N1 pandemic virus and bled
14 days later), positive human sera from RT-PCR positive
individuals collected in the convalescent phase, and nega-
tive human sera collected from non-infected individuals.
Positive sera had high titres by both HI and MN assays
against pandemic H1N1 viruses. Titres were expressed as
the reciprocal of the highest dilution of serum where hae-
magglutination was prevented. Individual seroconversion
was indicated by a four-fold or greater rise in titres
between successive samples.
Statistical Analysis
The data was analyzed using the Statistical Package for
the Social Sciences (SPSS, version 16.0, Chicago, IL) with
the level of significance set at 0.05. Categorical variables
were summarized as percentages and continuous vari-
ables as means with standard error (SE); the Student's T-
test was used to investigate the relationship between con-
tinuous variables.
Results
Outbreaks A, B and C occurred in 3 separate units on 22
Jun 09, 9 Jul 09 and 16 Jul 09 respectively. Prior to these
outbreaks, there were no increases of influenza-like ill-
ness or respiratory illness cases in these units, nor were
there any confirmed cases of 2009 Influenza A (H1N1).
Of the 252 personnel initially identified and sampled; 15
personnel were subsequently excluded as they had com-
pleted their conscript service and left the military before
completion of the study (Figure 1). The final study popu-
lation consisted of 237 personnel of which 11 personnel
were index cases of the outbreaks. These index cases were
started on treatment dose of oseltamivir (75 mg twice
daily for 5 days) and given medical leave at the onset of
the outbreak and thus did not have any baseline serology
taken.
The mean age of the study population was 21.2 years
old (range 18.7-30.8) (Table 1) and all were male, reflect-
ing the composition of the military. The ethnic make-up
was similar to the general Singapore population. Twenty-
three personnel (9.7%) had a history of asthma and 1
(0.4%) each had hypertension and IgA nephropathy; no
other relevant medical conditions were present.
Seroconversion During Prophylaxis (Table 2)
The overall infection rate of 2009 Influenza A (H1N1)
during the three outbreaks was 11.4% (27 personnel,
including 11 index cases). A total of 16 personnel (exclud-
ing index cases) developed a four-fold or higher rise in
antibody titres between the first and second blood sam-
ple, indicating infection whilst on oseltamivir prophy-
laxis. Of these, 8 (3.5% of the population) were
symptomatic - 6 had fever together with respiratory
symptoms while 2 had only respiratory symptoms. The
remaining 8 personnel (3.5%) were asymptomatic and
tested negative on PCR from consecutive nasopharyngeal
swabs.
Seroconversion Post-Prophyalxis
An additional 23 (12.1%) patients developed 4-fold rise in
antibody titres between the second and third blood sam-
ple, indicating infection after the cessation of prophylaxis
and up to the peak of the epidemic wave. Four (2.1%)
were symptomatic.
Antibody Titres
The baseline and post-seroconversion geometric mean
titres (GMT) of those who seroconverted during prophy-
laxis was 7.4 and 59.1 respectively (Table 3). The baseline
and post-seroconversion GMT of those who serocon-
verted post-prophylaxis was 6.6 and 62.9 respectively.
There was no significant difference in mean fold-rise in
GMT between the two groups (11.3 vs 11.7, p = 0.888).
Figure 1 Enrollment and Follow-up of Study Population.
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Ten index cases (ie given treatment dose of oseltamivir)
had a single post-seroconversion blood sample taken.
The post-seroconversion GMT for these index cases was
65.0 (SE 6.8) compared to 59.1 (SE 6.1) in those who sero-
converted during prophylaxis (p = 0.590).
Compliance and Side Effects
Of the 237 who started prophylaxis, 228 personnel
(96.2%) completed the full course of oseltamivir. Nine
personnel (3.8%) did not complete the full course due to
non-compliance and side effects; 5 (2.1%) complained of
nausea/vomiting. Of these 9 personnel, one was among
the symptomatic individuals who seroconverted, while
the other 8 did not have any symptoms and did not sero-
convert. No allergic, neuropsychiatric or other severe
side-effects were noted.
Discussion
Prophylaxis with oseltamivir has been shown to be effec-
tive in reducing the immediate spread of influenza in
community and household settings during the period of
administration [3,4]. However, the effectiveness of oselta-
mivir in reducing subsequent infection rates has not been
widely studied. Our study showed that prophylaxis may
be effective not only in reducing the spread of influenza
during a localized outbreak, but also after cessation of
prophylaxis during the overall epidemic. In our study, the
Table 1: Demographics of study population
Overall (n = 237) Outbreak A (n = 149) Outbreak B (n = 42) Outbreak C (n = 46)
Mean age (SE) (range) 21.2 (1.7)
(18.7-30.8)
21.1 (2.1) (18.7-30.8) 21.2 (0.8) (20.2-23.8) 21.2 (0.5) (20.1-22.4)
Median age (yr)
Male 237 (100%) 149 (100%) 42 (100%) 46 (100%)
Ethnicity
Chinese 175 (73.8%) 100 (67.1%) 36 (85.7%) 39 (84.8%)
Malay 41 (17.3%) 34 (22.8%) 4 (9.5%) 3 (6.5%)
Indian 12 (5.1%) 8 (5.4%) 1 (2.4%) 3 (6.5%)
Others 9 (3.8%) 7 (4.7%) 1 (2.4%) 1 (2.2%)
Significant medical history 25 (10.5%)* 21 (14.1%) 4 (9.5%) 0 (0.0%)
*All cases of significant medical history were asthma except 1 case of hypertension and 1 case of IgA nephropathy
Table 2: Seroconversion during and post-prophylaxis in the study population
Overall
(n = 237)
Outbreak A
(n = 149)
Outbreak B
(n = 42)
Outbreak C
(n = 46)
Date of 1st blood sample 23 Jun-16 Jul 10 23 Jun 10 9 Jul 10 16 Jul 10
Date of 2nd blood sample 13 Jul-6 Aug 10 13 Jul 10 30 Jul 10 6 Aug 10
Date of 3rd blood sample 21-25 Aug 10 21 Aug 10 25 Aug 10 25 Aug 10
Seroconversion during prophylaxis (second vs first 
samples)*
Total 16/226 (7.1%) 10/141 (7.1%) 4/40 (10%) 2/45 (4.4%)
Symptomatic 8/226 (3.5%) 3/141 (2.1%) 3/40 (7.5%) 2/45 (4.4%)
Asymptomatic (and RT-PCR negative) 8/226 (3.5%) 7/141 (5.0%) 1/40 (2.5%) 0/45 (0.0%)
Overall infection rate during outbreak (serological and 
index cases)
27/237 (11.4%) 18/149 (12.1%) 6/42 (14.3%) 3/46 (6.5%)
Seroconversion post-prophylaxis (third vs second samples)
Total 23/190 (12.1%) 16/115 (13.9%) 1/34 (2.9%) 6/41 (14.6%)
Symptomatic 4/190 (2.1%) 2/115 (1.7%) 1/34 (2.9%) 1/41 (2.4%)
Asymptomatic 19/190 (10.0%) 14/115 (12.2%) 0/34 (0.0%) 5/41 (12.2%)
*Excluding index casesLee et al. BMC Infectious Diseases 2010, 10:164
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overall infection rate during the outbreak was 11.4%. This
was lower than clinical attack rates in other seasonal
influenza outbreaks documented in the military- 57.7%
among Taiwanese military recruits [15] and 42% on a
navy ship [16]. Our infection rates were also lower when
compared to similar 2009 Influenza A (H1N1) outbreaks
in other closed communities - >30% attack rate in a
school outbreak [17] and 13-17% among household con-
tacts (which consisted of older age groups) [18].
The seroconversion rate after the cessation of prophy-
laxis until after the community epidemic's peak was
12.1%, which was similar to that of the initial outbreak
(11.4%). In addition, the overall combined infection rate
throughout the entire epidemic of 21.1% (50/237) was
lower than that of other similar military cohorts surveyed
in the Singapore military during the same period with a
seroconversion rate of 28% [19]. The latter cohorts did
not receive early oseltamivir prophylaxis. This shows that
anti-viral prophylaxis did not render the population more
susceptible to further outbreaks even though prophylaxis
was stopped 1-4 weeks before the peak of the epidemic.
On the contrary, anti-viral prophylaxis allowed cases to
be spread out across time, reducing peak absenteeism
and disruptions to the military or business continuity. A
previous study in another closed environment, a boarding
school, using amantadine post-exposure prophylaxis for
seasonal influenza A/H3N2 modeled that prophylaxis
reduced the number of clinical influenza-like illness cases
during its use by approximately 83.7%, and although the
number of cases increased upon cessation of prophylaxis,
the overall clinical attack rates were 21.7%, which was
lower than predicted using previous outbreaks for com-
parison [20].
Asymptomatic, RT-PCR negative seroconversion
occurred in 3.5% of the participants during oseltamivir
prophylaxis. This shows likely exposure to and infection
with 2009 Influenza A (H1N1), and the subsequent devel-
opment of antibodies which may be protective, without
increasing transmission. Furthermore, we found that the
antibody titres in those who seroconverted during pro-
phylaxis were not significantly different from those who
seroconverted after cessation of prophylaxis. As such, in
addition to preventing clinical infection, prophylaxis may
also result in asymptomatic infection and subsequent
immunity which provides individual protection against
further infection after cessation of prophylaxis, as well as
increasing herd immunity. The identical rates of symp-
tomatic and asymptomatic seroconversions during pro-
phylaxis show that the proportion of asymptomatic
infection is substantial and must be considered during
any influenza outbreak [21]. Our findings are similar to
the another study by Hayden and colleagues, which
showed that in the general community during seasonal
epidemic influenza, 2.3% to 2.5% of those who received
oseltamivir prophylaxis had asymptomatic infection,
although this was not significant compared to those on
placebo [3].
Our study provides evidence on serological infections
and asymptomatic seroconversion while on oseltamivir
prophylaxis, incorporating serological, PCR and clinical
data. However, there are some limitations of this study.
The lack of planned control groups which makes it diffi-
cult to assess the likely exposures and infection rates
within similar settings, but previous experiences have
suggested that exposures and infection rates during the
initial outbreak phase are high in closed environments
[15-17]. In addition, the age group in these outbreaks is
limited to young adults. Additional studies should be per-
formed in different populations and age groups, with
comparison groups to determine the overall effectiveness
of prophylaxis in reducing clinical infections and promot-
ing immunity.
Conclusion
Our study showed that post-exposure oseltmaivir pro-
phylaxis reduced the rate of infection in a vulnerable pop-
ulation and did not adversely increase subsequent
infection rates upon cessation of prophylaxis before the
epidemic's peak. In addition, we have shown that asymp-
tomatic seroconversions occur during prophylaxis, which
may confer protection against future infection. Post-
exposure prophylaxis remains a strategy to consider in
preventing the spread of influenza in closed environ-
ments and essential personnel populations.
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